9 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 enrolling by invitation. 12 Phase 2, 3 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 6, Not yet recruiting 3, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow this drug Literature Review of Sacituzumab govitecan (SG) trials Research Report on Sacituzumab govitecan (SG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer Trastuzumab emtansine (T-DM1), Trastuzumab deruxtecan (T-DXd), Datopotamab deruxtecan (Dato-DXd) - Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC) | Phase 2 | Not yet recruiting | Fudan University | 225 | 2026-09-10 | 2026-09-17 |
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC Zimberelimab (AB122), Domvanalimab (DOM), Sacituzumab Govitecan (SG) - Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Withdrawn | MedSIR | 2026-04-01 | 2026-05-01 | |
| First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients. Sacituzumab Govitecan (SG) - Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic | Phase 2 | Recruiting | Nathalie Levasseur | 24 | 2026-01-20 | 2026-10-06 |
| Saci Nivo Rela for TNBC Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab - Metastatic Triple-negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Yale University | 60 | 2025-12-29 | 2026-05-22 |
| A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel - Triple Negative Breast Neoplasms | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2025-09-01 | 2025-09-08 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors STAR0602, Sacituzumab Govitecan (SG) - Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 50 | 2025-03-24 | 2025-09-24 |
| Trop-2 Targeted PET Probes in Advanced TNBC Sacituzumab Govitecan (SG) - TNBC - Triple-Negative Breast Cancer | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 20 | 2025-03-01 | 2025-07-01 |
| Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence Sacituzumab Govitecan (SG), Nivolumab - Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 | Recruiting | University of California, Irvine | 23 | 2024-11-15 | 2026-04-30 |
| Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study Sacituzumab Govitecan (SG) - Breast Cancer, Brain Metastases From Breast Cancer | Recruiting | Peking University Cancer Hospital & Institute | 100 | 2024-08-01 | 2025-11-26 | |
| Sacituzumab Govitecan in Metastatic Colorectal Cancer Sacituzumab Govitecan (SG), Physicians Choice (PhC). - Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | University Hospital Heidelberg | 80 | 2024-04-19 | 2024-07-10 |
| Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC Sacituzumab Govitecan (SG), Bevacizumab - Advanced Breast Cancer | Phase 2 | Enrolling by invitation | YING FAN | 60 | 2024-04-01 | 2026-01-22 |
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Avelumab, Sacituzumab Govitecan (SG), M6223 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 256 | 2022-08-17 | 2026-09-28 |
| Sacituzumab Govitecan Plus EV in Metastatic UC Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab - Urothelial Cancer, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 106 | 2021-05-20 | 2025-11-04 |
Triple Negative Breast Neoplasms (5) · Breast Neoplasms (4) · Carcinoma, Transitional Cell (3) · Urinary Bladder Neoplasms (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1)
MedSIR (2) · Peking University Cancer Hospital & Institute (2) · Dana-Farber Cancer Institute (1) · EMD Serono Research & Development Institute, Inc. (1) · Fudan University (1) · Gilead Sciences (1) · Marengo Therapeutics, Inc. (1) · Nathalie Levasseur (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · University Hospital Heidelberg (1) · University of California, Irvine (1) · YING FAN (1) · Yale University (1)
China (6) · United States (6) · Canada (4) · Germany (3) · Australia (2) · Belgium (2) · France (2) · Greece (2) · Italy (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Argentina (1) · Brazil (1)
Adriana Kahn, MD (1) · Bradley A McGregor, MD (1) · Nataliya Mar, MD (1) · Tim Robinson, BMBS, PhD (1)
PMID 37671748, PMID 37871703, PMID 39929671
2023 (2), 2025 (2)